Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells

Gynecologic Oncology

Volumn 122, Issue 3, 2011, Pages 656-662

  Hoskins, Ebony ^a   Rodriguez Canales, Jaime ^a   Hewitt, Stephen M ^a   Elmasri, Wafic ^a   Han, Jasmine ^a   Han, Shing ^a   Davidson, Ben ^b   Kohn, Elise C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Metalloproteinase; MMP 9; Ovarian cancer; SLPI

Indexed keywords

GELATINASE B; PLASMIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER TISSUE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME RELEASE; EXPRESSION VECTOR; FEMALE; HUMAN; HUMAN TISSUE; MICROARRAY ANALYSIS; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINASE INHIBITION; TISSUE MICROARRAY; TRANSCRIPTION REGULATION; UPREGULATION; WILD TYPE;

CYSTADENOCARCINOMA, SEROUS; FEMALE; FIBRINOLYSIN; HUMANS; MATRIX METALLOPROTEINASE 9; OVARIAN NEOPLASMS; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; TRANSCRIPTION, GENETIC; TRANSFECTION; UP-REGULATION;

EID: 80051548874     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.04.052     Document Type: Article

References (39)

1. C.M. Annunziata, N. Azad, A.S. Dhamoon, G. Whiteley, and E.C. Kohn Ovarian cancer in the proteomics era Int J Gynecol Cancer 18 2008 1 6 (Pubitemid 351389045)
2. E.C. Kohn, N. Azad, C. Annunziata, A.S. Dhamoon, and G. Whiteley Proteomics as a tool for biomarker discovery Dis Markers 23 2007 411 417 (Pubitemid 350171262)
3. N. Angelov, N. Moutsopoulos, M.J. Jeong, S. Nares, G. Ashcroft, and S.M. Wahl Aberrant mucosal wound repair in the absence of secretory leukocyte protease inhibitor Thromb Haemost 92 2004 288 297 (Pubitemid 39172309)
4. L. Bingle, V. Singleton, and C.D. Bingle The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms Oncogene 21 2002 2768 2773 (Pubitemid 34478335)
5. M. Kobel, S.E. Kalloger, N. Boyd, S. McKinney, E. Mehl, and C. Palmer Ovarian carcinoma subtypes are different diseases: implications for biomarker studies PLoS Med 5 2008 e232
6. M.M. Tanner, S. Grenman, A. Koul, O. Johannsson, P. Meltzer, and T. Pejovic Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer Clin Cancer Res 6 2000 1833 1839 (Pubitemid 30305079)
7. J. Tapper, R. Butzow, T. Wahlstrom, M. Seppala, and S. Knuutila Evidence for divergence of DNA copy number changes in serous, mucinous and endometrioid ovarian carcinomas Br J Cancer 75 1997 1782 1787 (Pubitemid 27230704)
8. S. Tsukishiro, N. Suzumori, H. Nishikawa, A. Arakawa, and K. Suzumori Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis Gynecol Oncol 96 2005 516 519 (Pubitemid 40127158)
9. F.A. Simpkins, N.M. Devoogdt, N. Rasool, N.E. Tchabo, E.U. Alejandro, and M.M. Kamrava The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells Carcinogenesis 29 2008 466 472 (Pubitemid 351404861)
10. N. Devoogdt, N. Rasool, E. Hoskins, F. Simpkins, N. Tchabo, and E.C. Kohn Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo Cancer Sci 100 2009 434 440
11. N. Rasool, W. LaRochelle, H. Zhong, G. Ara, J. Cohen, and E.C. Kohn Secretory leukocyte protease inhibitor antagonizes paclitaxel in ovarian cancer cells Clin Cancer Res 16 2010 600 609
12. L.A. Liotta, and E.C. Kohn The microenvironment of the tumour-host interface Nature 411 2001 375 379
13. S. Curran, and G.I. Murray Matrix metalloproteinases in tumour invasion and metastasis J Pathol 189 1999 300 308 (Pubitemid 29489213)
14. M.L. Corcoran, R.E. Hewitt, D.E. Kleiner Jr., and W.G. Stetler-Stevenson MMP-2: expression, activation and inhibition Enzyme Protein 49 1996 7 19 (Pubitemid 26181734)
15. L. Devy, A. Noel, E. Baramova, K. Bajou, C. Trentesaux, and J.C. Jardillier Production and activation of matrix metalloprotease-9 (MMP-9) by HL-60 promyelocytic leukemia cells Biochem Biophys Res Commun 238 1997 842 846 (Pubitemid 27472663)
16. S. Chakraborti, M. Mandal, S. Das, A. Mandal, and T. Chakraborti Regulation of matrix metalloproteinases: an overview Mol Cell Biochem 253 2003 269 285
17. S.P. Eisenberg, K.K. Hale, P. Heimdal, and R.C. Thompson Location of the protease-inhibitory region of secretory leukocyte protease inhibitor J Biol Chem 265 1990 7976 7981
18. S.E. Williams, T.I. Brown, A. Roghanian, and J.M. Sallenave SLPI and elafin: one glove, many fingers Clin Sci (Lond) 110 2006 21 35 (Pubitemid 43059043)
19. E.C. Kohn, W. Jacobs, Y.S. Kim, R. Alessandro, W.G. Stetler-Stevenson, and L.A. Liotta Calcium influx modulates expression of matrix metalloproteinase-2 (72-kDa type IV collagenase, gelatinase A) J Biol Chem 269 1994 21505 21511 (Pubitemid 24274781)
20. C.M. Annunziata, H.T. Stavnes, L. Kleinberg, A. Berner, L.F. Hernandez, and M.J. Birrer Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer Cancer 116 2010 3276 3284
21. G.A. Sarosy, M.M. Hussain, M.V. Seiden, A.F. Fuller, N. Nikrui, and A. Goodman Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer Cancer 116 2010 1476 1484
22. C.M. Annunziata, L. Kleinberg, B. Davidson, A. Berner, D. Gius, and N. Tchabo BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancer Clin Cancer Res 13 2007 6585 6592 (Pubitemid 350206792)
23. W.E. Winter III, G.L. Maxwell, C. Tian, J.W. Carlson, R.F. Ozols, and P.G. Rose Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 3621 3627 (Pubitemid 47372600)
24. T.L. Moser, T.N. Young, G.C. Rodriguez, S.V. Pizzo, R.C. Bast Jr., and M.S. Stack Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma Int J Cancer 56 1994 552 559 (Pubitemid 24094407)
25. N. Devoogdt, G. Hassanzadeh Ghassabeh, J. Zhang, L. Brys, P. De Baetselier, and H. Revets Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells Proc Natl Acad Sci U S A 100 2003 5778 5782 (Pubitemid 36576884)
26. D. Belotti, C. Calcagno, A. Garofalo, D. Caronia, E. Riccardi, and R. Giavazzi Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion Mol Cancer Res 6 2008 525 534 (Pubitemid 351521834)
27. A.R. Farina, A. Coppa, A. Tiberio, A. Tacconelli, A. Turco, and G. Colletta Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity Int J Cancer 75 1998 721 730 (Pubitemid 28145819)
28. S. Uttamsingh, X. Bao, K.T. Nguyen, M. Bhanot, J. Gong, and J.L. Chan Synergistic effect between EGF and TGF-beta1 in inducing oncogenic properties of intestinal epithelial cells Oncogene 27 2008 2626 2634 (Pubitemid 351550880)
29. Y. Zhang, D.L. DeWitt, T.B. McNeely, S.M. Wahl, and L.M. Wahl Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases J Clin Invest 99 1997 894 900 (Pubitemid 27123626)
30. Y. St-Pierre, J. Couillard, and C. Van Themsche Regulation of MMP-9 gene expression for the development of novel molecular targets against cancer and inflammatory diseases Expert Opin Ther Targets 8 2004 473 489 (Pubitemid 39359652)
31. G.S. Ashcroft, K. Lei, W. Jin, G. Longenecker, A.B. Kulkarni, and T. Greenwell-Wild Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing Nat Med 6 2000 1147 1153
32. H.R. Lijnen Plasmin and matrix metalloproteinases in vascular remodeling Thromb Haemost 86 2001 324 333 (Pubitemid 32663963)
33. A. Noel, C. Gilles, K. Bajou, L. Devy, F. Kebers, and J.M. Lewalle Emerging roles for proteinases in cancer Invasion Metastasis 17 1997 221 239 (Pubitemid 29033880)
34. J.M. Chen, R.T. Aimes, G.R. Ward, G.L. Youngleib, and J.P. Quigley Isolation and characterization of a 70-kDa metalloprotease (gelatinase) that is elevated in Rous sarcoma virus-transformed chicken embryo fibroblasts J Biol Chem 266 1991 5113 5121 (Pubitemid 21909466)
35. V. Knauper, H. Will, C. Lopez-Otin, B. Smith, S.J. Atkinson, and H. Stanton Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme J Biol Chem 271 1996 17124 17131 (Pubitemid 26244262)
36. V. Dolo, S. D'Ascenzo, S. Violini, L. Pompucci, C. Festuccia, and A. Ginestra Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro Clin Exp Metastasis 17 1999 131 140 (Pubitemid 29335439)
37. C.C. Taggart, S.A. Cryan, S. Weldon, A. Gibbons, C.M. Greene, and E. Kelly Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding J Exp Med 202 2005 1659 1668 (Pubitemid 41815872)
38. E. Fakioglu, S.S. Wilson, P.M. Mesquita, E. Hazrati, N. Cheshenko, and J.A. Blaho Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism J Virol 82 2008 9337 9344
39. S. Weldon, and C.C. Taggart Innate host defense functions of secretory leucoprotease inhibitor Exp Lung Res 33 2007 485 491 (Pubitemid 350256095)